Published in Ann Intern Med on October 04, 2005
Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol (2010) 0.86
Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci (2008) 0.79
Proposed therapies in primary biliary cholangitis. Expert Rev Gastroenterol Hepatol (2016) 0.76
Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA (2002) 5.81
Alanine aminotransferase levels: what's normal? Ann Intern Med (2002) 2.17
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest (2002) 1.65
Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci (2010) 1.50
A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology (2004) 1.47
Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl (2004) 1.00
The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology (2013) 0.95
The natural history of PBC: has it changed? Semin Liver Dis (2005) 0.91
Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med (2003) 0.89
Management of primary sclerosing cholangitis. Am J Gastroenterol (2002) 0.88
Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol (2004) 0.88
Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci (2009) 0.86
A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci (2004) 0.84
Primary biliary cirrhosis: past, present, and future. Gastroenterology (2002) 0.82
Steroid-responsive (autoimmune?) sclerosing cholangitis. Dig Dis Sci (2005) 0.81
Persistent cholestatic jaundice after ERCP. Am J Gastroenterol (2006) 0.81
Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis. Hepatology (2002) 0.81
Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate. Am J Gastroenterol (2003) 0.81
Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology (2007) 0.80
Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol (2011) 0.80
Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol (2011) 0.79
Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci (2008) 0.79
Reversal of cirrhosis in a patient with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Dig Dis Sci (2005) 0.76
Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci (2010) 0.76
Reversal of portal hypertension in a patient with primary biliary cirrhosis: disappearance of esophageal varices and thrombocytopenia. Am J Gastroenterol (2004) 0.76
Development and prospective validation of a model for predicting weaning in chronic ventilator dependent patients. BMC Pulm Med (2003) 0.75
Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol. Hepatology (2009) 0.75
Reversible hepatic decompensation in primary biliary cirrhosis due to hypercoagulability. Ann Intern Med (2007) 0.75
Pericentral liver cell necrosis associated with the use of high-dose intravenous methylprednisolone. Dig Dis Sci (2007) 0.75
Reading and critically appraising systematic reviews and meta-analyses: a short primer with a focus on hepatology. J Hepatol (2005) 0.75